For nearly 50 years, Columbia has worked on numerous projects on the Walpole campus for Siemens Healthineers and its predecessors. Currently, the firm is providing Construction Management services for the largely completed advanced manufacturing and R&D facility expansion that consists of more than 40 interdependent renovations and additions to the five existing buildings on the Walpole campus, as well as a new office building as Siemens invests in innovation and increases their in vitro diagnostic manufacturing footprint in the United States. The facility currently employs more than 900 employees (1,300 by 2026) and is the main Siemens Healthineers manufacturing facility for assays that run on the ADVIA ® Centaur family of immunoassay instruments, and for consumables for the company’s molecular and blood gas testing instruments. R&D efforts at the site bring new tests to the in vitro diagnostics market to help physicians diagnose, monitor and treat diseases.
Phased implementation plans include multiple enabling projects critical to prevent any interruptions or reduction in existing production capacity.
“This investment demonstrates the company’s commitment to strong R&D and manufacturing capabilities that deliver robust innovation and an outstanding pipeline of products that are transforming care delivery. The U.S. is an extremely vital production location for Siemens Healthineers, as well as one of the most important research centers, and a key base from which the company exports globally.”
Deepak Nath, Ph.D.
President, Laboratory Diagnostics